Recap - First, W.V. Democratic Senator Joe Manchin introduced a bill last week to overturn the FDA’s marketing approval of Zohydro ER, an opioid pain product developed by Zogenix Inc. (ZGNX) and approved just last … Continue Reading
Read NowRecap - We ended the week with some commentary based largely on the strength observed in recent biotech stocks immediately following financings. It’s the momentum behind recent secondary offerings – … Continue Reading
Read NowRecap - Sarepta Therapeutics (SRPT) on Thursday morning released its fourth quarter and full-year 2013 financial results. The company continues to await guidance from the FDA on the … Continue Reading
Read NowRecap - Shares of Tekmira Pharmaceuticals (TKMR) have been on an absolute tear. Already since our January 7th reiteration to PropThink Premium members to own the stock, TKMR is up a … Continue Reading
Read NowRecap - Just remember – it’s not a win until you’ve locked in those profits. Buying Retrophin (RTRX) when PropThink suggested going long the stock on the day it up-listed to … Continue Reading
Read NowRecap - Incyte (INCY) has been one of PropThink’s most profitable recommendations in the last year. The stock is up nearly 190% since we first began covering the name in July of 2013. This … Continue Reading
Read NowRecap - It looked briefly at mid-week like the biotech sector’s correction might be a comical 48-hour event, but investors are in a tizzy over the emerging … Continue Reading
Read Now